Diabetes & Endocrinology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

This Phase 3 trial explored the use of setmelanotide, a medication designed for people with obesity caused by certain genetic changes in the MC4R pathway. Nearly 300 participants took part, and the study is now complete. The results could lead to a new targeted treatment option for individuals with rare genetic forms of obesity, a group that currently has few therapy choices.

QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes

Researchers in the United States completed a study testing a new conversation-based program for adults with type 2 diabetes. This approach encourages patients to share their concerns and priorities with their healthcare providers. The goal is to improve the overall care experience and help create diabetes management plans that better fit each person’s unique needs.

Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus

This ongoing trial in Thailand is studying whether a low-calorie diet paired with a personalized lifestyle program can help people with type 2 diabetes and overweight achieve remission from diabetes. The program includes tailored meal plans, exercise guidance, and blood sugar monitoring over six months. If successful, this approach could offer a non-medication path to better health and possibly reversing diabetes.

Trial to Evaluate Efficacy and Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients

The study is investigating an endoscopic procedure called Revita DMR for adults with type 2 diabetes who manage their condition without insulin. The goal is to see if this treatment can safely improve blood sugar control beyond what medications offer. Results are expected after 24 weeks of follow-up, potentially adding a new option for diabetes management.

Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity

This trial in Thailand compares two types of bariatric surgery for people with very severe obesity. It focuses on how each surgery affects hormone levels and the risk of low blood sugar after the procedure. Understanding these differences may help doctors choose surgical methods that reduce side effects and improve patient safety.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.